Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cells and IL-2 in Advanced Renal Cell or Urothelial Carcinoma
NCT06318871Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of cytokine-induced memory-like natural killer cells in renal cell carcinoma (RCC), urothelial carcinoma (UC), chromophobe renal cell carcinoma (chRCC) and 1 more (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Feasibility Failure Rate at 98 days. Started Aug 2024; status: active, not recruiting.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)chromophobe renal cell carcinoma (chRCC)Translocation Renal Cell Carcinoma (tRCC)
Beyond the preview
Go deeper on NCT06318871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318871.